SARAH CANNON
Fighting Cancer Together™

Available Clinical Trials

USOR Study #	Inclusion-ary Disease	Study Name	Sponsor	Phase	Stage(s)	Line of Therapy	Investiga-tional Drug	Drug Class	Mechanism of Action	Biomark-er(s)
22033	Biliary	TT-00420 (Tinengotinib) Tablet in Adult Patients with Advanced Cholangiocarcinoma	TransThera	II	III, IV	2+	Tinengotinib (TT-00420)	Spectrum-Selective Multi-Target Kinase Inhibitor	Aurora kinase A/B inhibitor; Receptor protein-tyrosine kinase antagonist	FGFR
22123		BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, & other select solid tumors	Boehringer Ingelheim	II	III, IV	2+	Brigimadlin (BI 907828)	MDM2-p53 Antagonist	Inhibits the interaction between the p53 and MDM2 proteins	MDM2
17079	Breast	MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Study)	AGENDIA	N/A	I, II, III	N/A	N/A	N/A	N/A	N/A
20210		Breast Cancer Index (BCI) Registry Study breast cancer index NOT ANOTHER MINUTE™	THERMOFISHER	IV	I, II, III	N/A	N/A	N/A	N/A	N/A
21270	Fallopian Tube	ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	zentalis	II	Any	2+	Azenosertib (ZN-c3)	WEE1 Inhibitor		N/A
21459	Head and Neck	CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)	CUE	I	Any	1st	CUE-101	Human Fusion Protein	Activates tumor-antigen-specific CD8+ T cells via delivery of reduced affinity mutant IL-2	HLA A*0201 HPV16+ p16INK4A
22311	Leukemia	Collection of Blood and Tissue Samples from Cancer Subjects (Non-Thyroid) for Validation of a Novel Blood-Based Multi-Cancer Screening Test	Harbinger Health	N/A	I, II, III, IV	N/A	N/A	N/A	N/A	N/A
20139	Lung	Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)	AstraZeneca	III	II, III	1st	Osimertinib (AZD9291)	EGFR TKI	Targets activating EGFR mutations, as well as the T790M-resistance mutation, through the formation of a covalent bond to the C797 residue in the ATP-binding site of mutant EGFR	EGFR Ex19del or L858R
20412		Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC	Lilly	III	I, II, III	2+	Selpercatinib (LY3527723)	RET Kinase Inhibitor	Selectively binds to and targets various RET mutants and RET-containing fusion	RET

Please reach out to CRC Maureen Lisowski for more information!
Maureen.Lisowski@alliancecancer.com

Available Clinical Trials

USOR Study #	Inclusion-ary Disease	Study Name	Sponsor	Phase	Stage(s)	Line of Therapy	Investiga-tional Drug	Drug Class	Mechanism of Action	Biomark-er(s)
21318	Lung	Alectinib Compared with Durvalumab in Patients with Locally Advanced, Unrectable, Stage III ALK Positive Non-Small Cell Lung Cancer after Concurrent or Sequential Chemoradiotherapy (BO42777)	Roche	III	III	2+	Alectinib (RO5424802)	ALK TKI	Inhibits ALK and RET proteins by preventing their phosphorylation	ALK
21498		Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203)	VERASTEM	II	III, IV	2nd, 3rd	Avutometinib (VS-6766)	MEK/RAF TKI	Blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK	KRAS G12C
22123		BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, & other select solid tumors	Boehringer Ingelheim	II	III, IV	2+	Brigimadlin (BI 907828)	MDM2-p53 antagonist	Inhibits the interaction between the p53 and MDM2 proteins	MDM2
22198		Furmonertinib Compared to Platinum-Based Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations	ARRIVENT	III	III, IV	1st	Furmonertinib (AST2818)	EGFR TKI	Irreversibly inhibits both EGFR sensitizing and T790M resistant mutations	EGFR exon 20 insertion
18263	Lymphoma	Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Acalabrutinib	BeiGene	II	Any	2+	Zanubrutinib (BGB-3111)	BTK Inhibitor	Forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity	N/A
22311		Collection of Blood and Tissue Samples from Cancer Subjects (Non-Thyroid) for Validation of a Novel Blood-Based Multi-Cancer Screening Test	Harbinger Health	N/A	I, II, III, IV	N/A	N/A	N/A	N/A	N/A
22311	Myeloma	Collection of Blood and Tissue Samples from Cancer Subjects (Non-Thyroid) for Validation of a Novel Blood-Based Multi-Cancer Screening Test	Harbinger Health	N/A	I, II, III, IV	N/A	N/A	N/A	N/A	N/A
21270	Ovarian	ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	zentalis	II	I, II, III, IV	2+	Azenosertib (ZN-c3)	WEE1 Inhibitor		N/A
22123	Pancreatic	BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, & other select solid tumors	Boehringer Ingelheim	II	III, IV	2+	Brigimadlin (BI 907828)	MDM2-p53 antagonist	Inhibits the interaction between the p53 and MDM2 proteins	MDM2
21270	Peritoneal	ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	zentalis	II	I, II, III, IV	2+	Azenosertib (ZN-c3)	WEE1 Inhibitor		N/A

Please reach out to CRC Maureen Lisowski for more information!
Maureen.Lisowski@alliancecancer.com

SARAH CANNON
Fighting Cancer Together™

Available Clinical Trials

USOR Study #	Inclusion-ary Disease	Study Name	Sponsor	Phase	Stage(s)	Line of Therapy	Investiga-tional Drug	Drug Class	Mechanism of Action	Biomark-er(s)
20138	**Prostate**	Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281)	AstraZeneca	III	IV	All	Capivasertib (AZD5363)	ATP-Competitive Inhibitor	Binds to and inhibits all AKT isoforms	PTEN
19151	**Solid Tumor**	Adagrasib (MRTX849) in Patients with Advanced Solid Tumors (No CRC, appendiceal, or NSCLC) with KRAS G12C Mutation	MIRATI	I/II	III, IV	All	Adagrasib (MRTX849)	KRAS G12C Inhibitor	Selectively and irreversibly binds to the KRAS G12C locking it in the inactive GDP bound state	KRAS G12C
20186		Tumor-agnostic Precision Immuno-oncology and somatic targeting rational for you (TAPISTRY)	Roche	II	III, IV	All	Entrectinib Alectinib Pralsetinib	TKIs	**Entrectinib:** binds to and blocks NTRK, ROS1 and anaplastic lymphoma kinase (ALK) overexpression **Alectinib:** Inhibits ALK and RET proteins by preventing their phosphorylation **Pralsetinib:** targets oncogenic RET alterations, including those that are resistant to multikinase inhibitors	ROS-1 NTRK1/2/3 ALK RET
22052		Nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes	AADI	II	III, IV	2+	nab-Sirolimus (ABI-009)	mTOR Inhibitor	Inhibition of mTOR	TSC1 TSC2
22311		Collection of Blood and Tissue Samples from Cancer Subjects (Non-Thyroid) for Validation of a Novel Blood-Based Multi-Cancer Screening Test	Harbinger Health	N/A	I, II, III, IV	N/A	N/A	N/A	N/A	N/A
22123	**Urothelial**	BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, & other select solid tumors	Boehringer Ingelheim	II	III, IV	2+	Brigimadlin (BI 907828)	MDM2-p53 antagonist	Inhibits the interaction between the p53 and MDM2 proteins	MDM2

Please reach out to CRC Maureen Lisowski for more information!
Maureen.Lisowski@alliancecancer.com